| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Animal Model |
From the Lombardi Cancer Center,*
Department of
Pharmacology,
Department of
Pathology,§
and School of
Nursing,
Georgetown University Medical
Center, Washington, DC; the Laboratory of
Pathology,¶
National Cancer Institute,
Bethesda, Maryland; and Southern Research Institute,||
Birmingham, Alabama
We have previously shown that fibroblast growth factor (FGF)-1-, FGF-4-, or vascular endothelial growth factor (VEGF/VPF)-transfected MCF-7 breast carcinoma cells growing as tumors in nude mice are tamoxifen resistant and/or estrogen independent. These transfectants provide opportunity for study of in situ tumor-induced angiogenesis promoted by the individual angiogenic factors under growth-promoting versus growth-inhibiting hormonal conditions. In the present study, vessels in tumors harvested at varying times after tumor cell injection were immunohistochemically highlighted and vessel morphology and topography were scored on a scale of 0 to 4 by blinded observers. In tumors produced by all cell lines under all growth-promoting hormonal conditions, there was significantly increased abundance (P < 0.05) of edge-associated and intratumor microvessels, but not of stromally located microvessels, when compared with tumor nodules harvested under growth-inhibiting conditions, regardless of the identity of the angiogenic factor or the hormonal treatment. Image analysis of bromodeoxyuridine (BrdU)-labeled nuclei of tumors produced by all cell lines under all hormonal conditions harvested at early time points showed that mean labeling indices were highest for hormonal conditions that produced the most robust growth in that particular cell line, implying that a high BrdU labeling index is a predictor of future tumor growth in individual tumors. These results confirm previous studies that established the importance of neovascularization for tumor growth and provide validation for use of these cell lines to study the process of angiogenesis in vivo. Study of gene expression in endothelial cells in edge-associated or intratumor vessels using this model might reveal mechanisms important in tumor-induced angiogenesis in human breast cancer.
This article has been cited by other articles:
 |
|
 |
|
  S. Akhtar, S. M. Meeran, N. Katiyar, and S. K. Katiyar Grape Seed Proanthocyanidins Inhibit the Growth of Human Non-Small Cell Lung Cancer Xenografts by Targeting Insulin-Like Growth Factor Binding Protein-3, Tumor Cell Proliferation, and Angiogenic Factors Clin. Cancer Res., February 1, 2009; 15(3): 821 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Qu, S. Van Ginkel, A. M. Roy, L. Westbrook, M. Nasrin, Y. Maxuitenko, A. R. Frost, D. Carey, W. Wang, R. Li, et al. Vascular Endothelial Growth Factor Reduces Tamoxifen Efficacy and Promotes Metastatic Colonization and Desmoplasia in Breast Tumors Cancer Res., August 1, 2008; 68(15): 6232 - 6240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M Hyder Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yano, Y. Fujii, A. Iwai, Y. Kageyama, and K. Kihara Glucocorticoids Suppress Tumor Angiogenesis and In vivo Growth of Prostate Cancer Cells. Clin. Cancer Res., May 15, 2006; 12(10): 3003 - 3009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Miller, M. Miller, S. Mehrotra, B. Agarwal, B. H. Mock, Q.-H. Zheng, S. Badve, G. D. Hutchins, and G. W. Sledge Jr. A Physiologic Imaging Pilot Study of Breast Cancer Treated with AZD2171 Clin. Cancer Res., January 1, 2006; 12(1): 281 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Miller, L. I. Chap, F. A. Holmes, M. A. Cobleigh, P. K. Marcom, L. Fehrenbacher, M. Dickler, B. A. Overmoyer, J. D. Reimann, A. P. Sing, et al. Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer J. Clin. Oncol., February 1, 2005; 23(4): 792 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Guo, Q. Fang, H.-Q. Tao, C. A. Schafer, B. M. Fenton, I. Ding, B. Hu, and S.-Y. Cheng Overexpression of Vascular Endothelial Growth Factor by MCF-7 Breast Cancer Cells Promotes Estrogen-independent Tumor Growth in Vivo Cancer Res., August 1, 2003; 63(15): 4684 - 4691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sacchini, S. Zurrida, G. Andreoni, A. Luini, V. Galimberti, P. Veronesi, M. Intra, G. Viale, and U. Veronesi Pathologic and Biological Prognostic Factors of Breast Cancers in Short- and Long-Term Hormone Replacement Therapy Users Ann. Surg. Oncol., April 1, 2002; 9(3): 266 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Inoue, J. W. Slaton, B. Y. Eve, S. J. Kim, P. Perrotte, M. D. Balbay, S. Yano, M. Bar-Eli, R. Radinsky, C. A. Pettaway, et al. Interleukin 8 Expression Regulates Tumorigenicity and Metastases in Androgen-independent Prostate Cancer Clin. Cancer Res., May 1, 2000; 6(5): 2104 - 2119. [Abstract] [Full Text]
|
|
|
|
|
|
K. Inoue, J. W. Slaton, S. J. Kim, P. Perrotte, B. Y. Eve, M. Bar-Eli, R. Radinsky, and C. P. N. Dinney Interleukin 8 Expression Regulates Tumorigenicity and Metastasis in Human Bladder Cancer Cancer Res., April 1, 2000; 60(8): 2290 - 2299. [Abstract] [Full Text]
|
|
|
|
|
|
L. Zhang, S. Kharbanda, S. W. McLeskey, and F. G. Kern Overexpression of Fibroblast Growth Factor 1 in MCF-7 Breast Cancer Cells Facilitates Tumor Cell Dissemination but Does Not Support the Development of Macrometastases in the Lungs or Lymph Nodes Cancer Res., October 1, 1999; 59(19): 5023 - 5029. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
